Urogen Pharma Ltd (NASDAQ:URGN) – Investment analysts at Jefferies Group raised their Q4 2017 earnings per share estimates for shares of Urogen Pharma in a research report issued to clients and investors on Tuesday. Jefferies Group analyst M. Andrews now forecasts that the company will post earnings per share of ($0.60) for the quarter, up from their prior forecast of ($0.67). Jefferies Group also issued estimates for Urogen Pharma’s FY2018 earnings at ($2.24) EPS, FY2019 earnings at ($2.34) EPS, FY2020 earnings at ($1.26) EPS and FY2021 earnings at ($0.75) EPS.
Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.10).
Shares of Urogen Pharma (URGN) opened at $50.64 on Thursday. Urogen Pharma has a one year low of $13.01 and a one year high of $56.56.
Several institutional investors have recently made changes to their positions in URGN. State of Tennessee Treasury Department bought a new position in Urogen Pharma in the 3rd quarter worth approximately $158,000. Clal Insurance Enterprises Holdings Ltd bought a new position in Urogen Pharma in the 4th quarter worth approximately $166,000. JPMorgan Chase & Co. bought a new position in Urogen Pharma in the 3rd quarter worth approximately $168,000. MYDA Advisors LLC bought a new position in Urogen Pharma in the 4th quarter worth approximately $223,000. Finally, Goldman Sachs Group Inc. bought a new position in Urogen Pharma in the 4th quarter worth approximately $234,000. Institutional investors and hedge funds own 32.63% of the company’s stock.
In other news, major shareholder Proquest Investments Iv, L.P. sold 209,298 shares of the stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $40.60, for a total transaction of $8,497,498.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
COPYRIGHT VIOLATION NOTICE: “Research Analysts Set Expectations for Urogen Pharma Ltd’s Q4 2017 Earnings (URGN)” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/15/research-analysts-set-expectations-for-urogen-pharma-ltds-q4-2017-earnings-urgn.html.
About Urogen Pharma
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.